Refractory gastrooesophageal reflux disease

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 3, 2008, Pages 217-223

  Bredenoord, Albert J ^a   Smout, André J ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acid; Fundoplication; Gastrooesophageal reflux; Heartburn; Oesophageal; Proton pump inhibitor

Indexed keywords

BACLOFEN; CORTICOSTEROID; CYTOCHROME P450 2C19; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

AEROPHAGIA; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; DRUG EFFICACY; DRUG METABOLISM; DYSPEPSIA; EOSINOPHILIC ESOPHAGITIS; ESOPHAGUS ACHALASIA; EVENING DOSAGE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GENOTYPE; HELICOBACTER PYLORI; HUMAN; LARYNGITIS; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RUMINATION; STOMACH PH; TREATMENT FAILURE; TREATMENT RESPONSE; ZOLLINGER ELLISON SYNDROME;

CIRCADIAN RHYTHM; DIAGNOSIS, DIFFERENTIAL; DYSPEPSIA; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; PATIENT COMPLIANCE; PROTON PUMP INHIBITORS; TREATMENT FAILURE;

EID: 39849101874     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f1cc39     Document Type: Review

References (70)

1. Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut 2004; 53 (Suppl 4): iv1-iv24.
2. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidencebased consensus. Am J Gastroenterol 2006; 101:1900-1920.
3. Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001; 15:227-231.
4. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000; 95:3071-3080.
5. Hatlebakk JG, Berstad A. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. Aliment Pharmacol Ther 1997; 11:1093-1099.
6. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17:537-545.
7. Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-979.
8. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656-664.
9. Frazzoni M, De Micheli E, Zentilin P, Savarino V. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004; 20: 81-88.
10. Johnston BT, Lewis SA, Collins JS, McFarland RJ, Love AH. Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors. Scand J Gastroenterol 1995; 30:1-5.
11. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-1479.
12. Delaney B, Ford AC, Forman D, Moayyedi P, Qume M. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2005:CD001961.
13. Tutuian R, Castell DO. Rumination documented by using combined multichannel intraluminal impedance and manometry. Clin Gastroenterol Hepatol 2004; 2:340-343.
14. Bredenoord AJ,Weusten BL, Timmer R, Smout AJ. Air swallowing, belching, and reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2006; 101:1721-1726.
15. Bredenoord AJ, Weusten BL, Sifrim D, Timmer R, Smout AJ. Aerophagia, gastric, and supragastric belching: a study using intraluminal electrical impedance monitoring. Gut 2004; 53:1561-1565.
16. Chitkara DK, Bredenoord AJ, Tucker MJ, Talley NJ. Aerophagia in adults: a comparison of presenting symptoms with functional dyspepsia. Aliment Pharmacol Ther 2005; 22:855-858.
17. Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Psychological factors affect the frequency of belching in patients with aerophagia. Am J Gastroenterol 2006; 101:2777-2781.
18. Katz PO, Dalton CB, Richter JE,Wu WC, Castell DO. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. Ann Intern Med 1987; 106:593-597.
19. Lee RG. Marked eosinophilia in esophageal mucosal biopsies. Am J Surg Pathol 1985; 9:475-479.
20. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007; 5:4-16.
21. Remedios M, Campbell C, Jones DM, Kerlin P. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 2006; 63:3-12.
22. Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003; 125:1660-1669.
23. Klinkenberg-Knol EC, Meuwissen SG. Combined gastric and oesophageal 24-h pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther 1990; 4:485-495.
24. Bardhan KD, Achim A, Riddermann T, Pfaffenberger B. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007; 25:1461-1469.
25. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with protonpump inhibitors as a test for gastroesophageal reflux disease: a metaanalysis of diagnostic test characteristics. Ann Intern Med 2004; 140: 518-527.
26. Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 2000; 119:670-676.
27. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 1259-1266.
28. Egan LJ, Myhre GM, Mays DC, Dierkhising RA, Kammer PP, Murray JA. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003; 17:1521-1528.
29. Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17:965-973.
30. Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91:1527-1531.
31. Verdu EF, Armstrong D, Fraser R, Viani F, Idstrom JP, Cederberg C, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36:539-543.
32. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117:11-16.
33. Spechler SJ, Sharma P, Traxler B, Levine D, Falk GW. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol 2006; 101:1964-1971.
34. Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 2004; 16:441-443.
35. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93:763-767.
36. Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002; 16:1309-1316.
37. Orr WC, Harnish MJ. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003; 17: 1553-1558.
38. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98:545-550.
39. Silny J. Intraluminal multiple electric impedance procedure for measurement of gastrointestinal motility. J Gastrointest Mot 1991; 3:151-162.
40. Wise J, Murray JA. Utilising multichannel intraluminal impedance for diagnosing GERD: a review. Dis Esophagus 2007; 20:83-88.
41. Sifrim D, Holloway R, Silny J, Xin Z, Tack J, Lerut A, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-h pH-impedance recordings. Gastroenterology 2001; 120:1588-1598.
42. Zerbib F, Roman S, Ropert A, des Varannes SB, Pouderoux P, Chaput U, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101:1956-1963.
43. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120:1599-1606.
44. Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation. Gut 2005; 55:313-318.
45. Flood CA, Fink S, Mathers J. Pain due to esophageal distention. Am J Dig Dis 1963; 8:632-638.
46. Mittal RK. Measuring esophageal distention by high-frequency intraluminal ultrasound probe. Am J Med 2003; 115 (Suppl 3A):130S-136S.
47. Koek GH, Tack J, Sifrim D, Lerut T, Janssens J. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol 2001; 96:2033-2040.
48. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005; 50:81-85.
49. Netzer P, Gut A, Brundler R, Gaia C, Halter F, Inauen W. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. Aliment Pharmacol Ther 2001; 15:1375-1384.
50. Marshall RE, Anggiansah A, Manifold DK, Owen WA, Owen WJ. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. Gut 1998; 43:603-606.
51. Menges M, Muller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol 2001; 96:331-337.
52. Vaezi MF, Lacamera RG, Richter JE. Validation studies of Bilitec 2000: an ambulatory duodenogastric reflux monitoring system. Am J Physiol 1994; 267:G1050-G1057.
53. Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99:981-988.
54. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and nonacid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17:243-251.
55. Bredenoord AJ, Draaisma WA, Weusten BL, Gooszen HG, Smout AJ. Mechanisms of acid, weakly acidic and gas reflux after anti-reflux surgery. Gut 2008; 57:161-166.
56. Vaezi MF, Hicks DM, Abelson TI, Richter JE. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. Clin Gastroenterol Hepatol 2003; 1:333-344.
57. Qadeer MA, Phillips CO, Lopez AR, Steward DL, Noordzij JP,Wo JM, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101:2646-2654.
58. Wunderlich AW, Murray JA. Temporal correlation between chronic cough and gastroesophageal reflux disease. Dig Dis Sci 2003; 48:1050-1056.
59. Sifrim D, Dupont L, Blondeau K, Zhang X, Tack J, Janssens J. Weakly acidic reflux in patients with chronic unexplained cough during 24 h pressure, pH, and impedance monitoring. Gut 2005; 54:449-454.
60. Fass R, Sampliner RE, Malagon IB, Hayden CW, Camargo L, Wendel CS, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000; 14:597-602.
61. Helm JF, Dodds WJ, Riedel DR, Teeter BC, Hogan WJ, Arndorfer RC. Determinants of esophageal acid clearance in normal subjects. Gastroenterology 1983; 85:607-612.
62. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994; 89:1844-1848.
63. Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12:893-897.
64. Fass R, Murthy U, Hayden CW, Malagon IB, Pulliam G, Wendel C, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14:1595-1603.
65. Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut 2005; 54: 1810-1817.
66. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100:283-289.
67. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, et al. Acid and nonacid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicenter study using combined ambulatory impedance-pH monitoring. Gut 2006; 55:1398-1402.
68. Fouad YM, Katz PO, Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999; 13:1467-1471.
69. Fibbe C, Layer P, Keller J, Strate U, Emmermann A, Zornig C. Esophageal motility in reflux disease before and after fundoplication: a prospective, randomized, clinical, and manometric study. Gastroenterology 2001; 121: 5-14.
70. Timmer R, Breumelhof R, Nadorp JH, Smout AJ. Esophageal motility in low-grade reflux esophagitis, evaluated by stationary and 24-h ambulatory manometry. Am J Gastroenterol 1993; 88: 837-841.